iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors (PR Newswire)

iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors

UF startup iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing cutting-edge immunotherapies for solid tumors.

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the seamless continuation of TargImmune’s research into novel tumor-targeted RNA therapies while benefiting from iOncologi’s expanded resources and strategic vision.

Read more about iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors.